What Is BPC-157?

BPC-157, commonly expanded as “Body Protection Compound-157,” is a synthetic pentadecapeptide composed of 15 amino acids. It was developed from research involving a protective protein fraction found in human gastric juice.

Major research themes

• Gastric and intestinal cytoprotection
• Tendon, ligament, muscle, and bone healing
• Fibroblast migration and collagen organization
• Angiogenesis and endothelial signaling
• Nitric-oxide pathway modulation
• Nerve and neuromuscular recovery

🧬 Structure, Sequence, and Molecular Properties

🧪 Amino-acid sequence

H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH

GEPPPGKPADDAGLV

BPC-157 may be supplied as free peptide, acetate salt, or TFA salt. Counterions and water can materially increase gross powder weight, so net peptide content is not the same as total vial weight.

Origin and Naming

BPC-157 was described as a stable 15-residue fragment related to a larger protective gastric protein fraction. The commercial research peptide is synthetically manufactured. The exact endogenous precursor, physiological concentration, receptor, and natural processing pathway remain incompletely established.

📅 Research Timeline

• 1990s: Early animal studies described gastric and systemic cytoprotection.
• 2000s: Research expanded into ulcers, fistulas, vascular effects, tendons, and organ injury.
• 2011: Tendon-fibroblast work reported enhanced migration and FAK-paxillin signaling.
• 2021: A small uncontrolled knee-pain report described intra-articular use.
• 2022: WADA added BPC-157 to its Prohibited List.
• 2023–2024: FDA highlighted significant safety concerns for compounded BPC-157.
• 2025: A two-person intravenous pilot reported no adverse effects at the tested exposures.
• 2026: Orthopaedic reviews continued to classify the evidence as predominantly preclinical.

🧠 How Might BPC-157 Work?

Nitric-oxide signaling

Animal studies report interactions with nitric-oxide synthase pathways and effects during both nitric-oxide excess and blockade.

Angiogenesis and endothelium

Reported mechanisms include VEGF-related signaling, endothelial migration, vascular repair, and collateral-vessel recruitment.

FAK-paxillin signaling

Tendon fibroblast research reported activation of focal adhesion kinase and paxillin pathways associated with migration and adhesion.

Growth-factor and cytoprotective signaling

Experimental work has examined VEGF, Egr-1, growth-hormone receptor, epithelial preservation, and broader cytoprotective responses.

Gastrointestinal Research

Animal studies report reduced injury and improved healing in models involving gastric ulcers, NSAID damage, alcohol injury, colitis, intestinal anastomoses, fistulas, obstruction, and short-bowel injury. Proposed effects include epithelial preservation, improved blood flow, reduced inflammation, and restored mucosal integrity. No large randomized human trial has established efficacy for ulcers, inflammatory bowel disease, or fistulas.

Tendon, Ligament, Muscle, and Bone Research

Preclinical studies report enhanced tendon fibroblast migration, FAK-paxillin signaling, collagen organization, vascularization, tendon continuity, and biomechanical recovery. Animal work also includes ligament injury, muscle trauma, neuromuscular-junction preservation, fractures, bone defects, and tendon-to-bone healing. Controlled human trials are lacking.

Vascular and Nitric-Oxide Research

BPC-157 has been associated with endothelial protection, vascular adaptation, collateral circulation, and reduced ischemic injury in animal occlusion models. Research groups have also reported effects in thrombosis, bleeding, and blood-pressure models. These findings require independent replication and careful translation because angiogenesis and vascular modulation are not universally beneficial.

Nerve and Neurological Research

Animal studies include peripheral nerve injury, muscle reinnervation, spinal cord injury, traumatic brain injury, stroke, dopamine and serotonin disruption, and neuromuscular damage. No controlled human trial has established efficacy for neuropathy, spinal injury, stroke, or neurodegenerative disease.

Human Evidence

Two-person intravenous pilot

A 2025 pilot administered intravenous BPC-157 to two healthy adults and reported no adverse effects at the studied exposures. This sample is too small to establish safety, detect uncommon events, or support efficacy.

Small knee-pain report

A 2021 uncontrolled retrospective report described improvement in a small group receiving intra-articular BPC-157, with some receiving thymosin beta-4 as well. It lacked randomization, placebo control, standardized imaging outcomes, and rigorous follow-up.

Major unknowns

• Human pharmacokinetics and half-life
• Bioavailability by route
• Therapeutic window
• Long-term organ safety
• Immunogenicity
• Drug interactions
• Reproductive safety
• Clinical efficacy for any condition

FDA, Compounding, and Anti-Doping Status

BPC-157 is not FDA approved. FDA has stated that compounded BPC-157 may pose immunogenicity and impurity-characterization risks and that available information is insufficient to determine whether administration would harm humans. BPC-157 is prohibited at all times under WADA rules.

Potential Side Effects and Safety Considerations

There is no established human safety profile. Potential risks include injection-site reactions, infection, hypersensitivity, anti-peptide antibodies, endotoxin, particles, incorrect sequence or strength, unknown liver and kidney effects, unknown coagulation and blood-pressure effects, and unknown reproductive risk.

Potential interactions with anticoagulants, antiplatelet agents, nitric-oxide drugs, NSAIDs, psychiatric medicines, blood-pressure drugs, and chemotherapy have not been adequately studied.

🧪 Laboratory Testing Methods

📄 How to Interpret a BPC-157 COA

1. Verify the complete GEPPPGKPADDAGLV sequence.
2. Confirm intact mass near 1419.5 Da.
3. Use MS/MS rather than intact mass alone.
4. Confirm L stereochemistry.
5. State free N terminus and C-terminal acid unless modified.
6. State acetate, TFA, or other salt form.
7. Report net peptide content after correcting for water and counterions.
8. Measure deletion peptides, epimers, oxidized products, and synthesis impurities.
9. Assess proline-related conformers.
10. Include protease stability.
11. Use a qualified migration, endothelial, matrix, or nitric-oxide potency assay.
12. For finished injectables, require sterility, endotoxin, particles, fill accuracy, container closure, and post-reconstitution stability.
13. A COA does not prove human safety, efficacy, or FDA approval.

📊 Comparison Tables

BPC-157 vs TB-500 vs GHK-Cu vs KPV

BPC-157 vs Larazotide vs KPV for Gut Research

Raw BPC-157 vs Research-Qualified Material

🖼️ Original Diagram Specifications

1. Full sequence with proline-rich region highlighted.
2. Mechanism map showing endothelium, nitric oxide, FAK-paxillin, VEGF, fibroblasts, and collagen.
3. Gastrointestinal injury and epithelial-restoration diagram.
4. Tendon-repair cascade with fibroblast migration and collagen organization.
5. Evidence pyramid from animal studies to sparse human reports.
6. Risk map covering immunogenicity, impurities, angiogenesis, contamination, interactions, and WADA status.
7. COA workflow with sequence, chirality, mass, salt correction, conformers, potency, sterility, and stability.

❓ Frequently Asked Questions

Is BPC-157 a peptide?

Yes. It is a synthetic linear 15-amino-acid peptide.

What is the sequence?

GEPPPGKPADDAGLV.

What is the molecular formula?

C₆₂H₉₈N₁₆O₂₂.

What is the molecular weight?

Approximately 1419.5 Da.

Is it FDA approved?

No.

What is it studied for?

Gastrointestinal protection, tendon and muscle repair, vascular signaling, nitric oxide, nerves, and organ-injury models.

Does it heal tendons?

Animal and cell studies are promising, but controlled human evidence is lacking.

Has it been tested in humans?

Only very limited reports exist, including a two-person intravenous pilot and a small uncontrolled knee-pain report.

Is it safe?

There is not enough human evidence to establish general safety.

Is it prohibited in sports?

Yes.

Does 99% HPLC prove quality?

No. Sequence, stereochemistry, salt, net content, impurities, potency, sterility, and stability also matter.

Is there an established injectable dose?

No.

Final Thoughts

BPC-157 is a 15-residue synthetic peptide with a remarkably broad preclinical claim profile. Animal studies report effects across gastrointestinal injury, tendons, ligaments, muscle, bone, vessels, nerves, brain, and multiple organs.

The recurring themes include cytoprotection, endothelial stabilization, nitric-oxide regulation, angiogenesis, fibroblast migration, FAK-paxillin signaling, and collagen organization. However, no accepted primary receptor has been established.

The central problem is translation. Human evidence remains extraordinarily limited, while FDA continues to highlight immunogenicity, impurity-characterization, and insufficient human-safety concerns. WADA prohibits the peptide.

Analytical authentication requires the complete sequence, L stereochemistry, correct termini, intact mass, salt form, net content, conformer and impurity profiling, potency, protease stability, and route-specific microbiological quality. A polished COA cannot replace missing clinical evidence.

📚 References

1. Józwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals. 2025.
2. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. 2025.
3. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. 2025.
4. Lee E, et al. Safety of Intravenous Infusion of BPC157 in Humans. 2025.
5. Lee E, et al. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. 2021.
6. Chang CH, et al. The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing. Journal of Applied Physiology. 2011.
7. Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021.
8. Xu C, et al. Preclinical Safety Evaluation of BPC-157. Regulatory Toxicology and Pharmacology. 2020.
9. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. 2026.
10. Rahman OF, et al. Therapeutic Peptides in Orthopaedics. 2026.
11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks: BPC-157.
12. World Anti-Doping Agency. 2026 Prohibited List.
13. International Council for Harmonisation. ICH Q1A(R2), Q2(R2), Q3A, Q3B, Q3C, and Q6B.
14. United States Pharmacopeia General Chapters <621>, <71>, <85>, and <788>.

Sequence, chemistry, preclinical and human evidence, FDA and WADA status, safety, and analytical information reviewed in July 2026.